rs324011 — STAT6

STAT6 — The Th2 Master Switch That Sets Your Allergy Thermostat

STAT6 (Signal Transducer and Activator of Transcription 6)¹¹ STAT6 (Signal Transducer and Activator of Transcription 6)
A transcription factor activated by interleukin-4 (IL-4) and interleukin-13 (IL-13) that drives Th2 immune responses — the arm of the immune system responsible for allergy, asthma, and eczema. When IL-4 or IL-13 binds its receptor, STAT6 becomes phosphorylated, dimerizes, and migrates to the nucleus where it switches on genes for IgE production, eosinophil recruitment, and airway remodeling is the central transcription factor of the Th2 immune axis — the pathway that governs allergic disease. The rs324011 variant, located in intron 2 of the STAT6 gene on chromosome 12, is one of the most studied intronic polymorphisms in atopic disease genetics. Unlike missense variants that alter the protein's structure, this variant acts as a regulatory switch: it controls how much STAT6 gets made in the first place.

The Mechanism

The rs324011 variant lies within the second intron of STAT6, in a region that influences the gene's transcriptional regulation. The T allele creates a functional NF-κB binding site²² NF-κB binding site
NF-κB (Nuclear Factor kappa B) is a master inflammatory transcription factor that, when activated by immune signals, binds to specific DNA sequences and drives expression of inflammatory genes; creating a new binding site in the STAT6 gene means NF-κB can now directly upregulate STAT6 transcription. A luciferase reporter assay³³ luciferase reporter assay
A laboratory technique where the gene's regulatory region is fused to a light-emitting reporter gene; more light = more transcription confirmed that the T allele of rs324011 significantly increases STAT6 promoter activity compared to the C allele. The biological consequence is straightforward: cells with the T allele make more STAT6 protein, so the same IL-4 or IL-13 signal generates a stronger Th2 response.

The C allele does not create this NF-κB binding site, leaving STAT6 under tighter transcriptional control. This difference in gene dosage is enough to produce measurable differences in circulating IgE levels — the antibody class that orchestrates allergic reactions through mast cell and basophil activation.

The Evidence

The clearest functional evidence comes from a Taiwanese cohort study. Lee et al. 2015⁴⁴ Lee et al. 2015
Taiwan Children Health Study; STAT6 genetic variants and childhood atopic dermatitis in a Taiwanese population; J Dermatol Sci 2015 found that the T allele was associated with childhood atopic dermatitis with an odds ratio of 1.23 (95% CI 1.01–1.51), and functionally validated the NF-κB mechanism using luciferase reporter assays in cell lines.

At the population level, Weidinger et al. 2004⁵⁵ Weidinger et al. 2004
J Med Genet; 1,407 German adults from the KORA cohort showed that rs324011 is significantly associated with total serum IgE (p=0.015), and that a STAT6 haplotype carrying this variant drove a dose-response relationship across IgE percentiles — OR 1.7 at the 100 kU/L threshold rising to OR 2.54 at the 90th percentile for very high IgE. The dose-response pattern across IgE thresholds supports a genuine causal relationship rather than a statistical artifact.

A meta-analysis of six studies totaling 1,431 asthma cases and 2,027 controls Qian et al. 2014⁶⁶ Qian et al. 2014
Hum Immunol; meta-analysis of STAT6 polymorphisms and asthma risk found that TT homozygotes had a 26–29% higher asthma risk compared to CT+CC (recessive model OR 1.26, 95% CI 1.02–1.55). The 2017 GWAS from Ferreira et al. using 360,838 participants with asthma, hay fever, and eczema confirmed the STAT6 locus among the 136 shared genetic risk variants for atopic disease.

Practical Implications

For T allele carriers, the elevated STAT6 expression creates a lower threshold for Th2 immune activation, meaning atopic reactions (eczema flares, allergic rhinitis, asthma) may be triggered by lower allergen exposures than in CC individuals. Total serum IgE — a direct readout of this pathway — is a clinically available biomarker that can quantify how active the Th2 axis currently is and whether interventions are working.

Quercetin⁷⁷ Quercetin
A flavonoid found in onions, apples, capers, and supplemented as a powder or capsule; acts as a natural STAT6 and NF-κB inhibitor at concentrations achievable in cell culture; evidence is mechanistic rather than from clinical trials has been shown in vitro to inhibit STAT6 phosphorylation and suppress IL-5 and IL-13 production from CD4+ T cells, directly targeting the pathway this variant upregulates. This is a biologically rational intervention for T allele carriers, though clinical trial data in atopic disease are limited.

Pharmacogenomically, dupilumab (Dupixent) — the monoclonal antibody blocking the shared IL-4/IL-13 receptor subunit (IL-4Rα) — directly counteracts the molecular pathway amplified by this variant. While prescribing decisions for dupilumab are currently based on clinical severity rather than genotype, carriers of the T allele who develop moderate-to-severe atopic dermatitis or asthma are operating in a pathway biologically well-matched to dupilumab's mechanism of action.

Interactions

The rs324011 variant acts in the same Th2 signaling axis as IL13 rs20541 (R130Q), which produces a hyperactive IL-13 protein that drives stronger STAT6 activation downstream. Carriers of risk alleles at both loci face a double amplification: more STAT6 protein (rs324011-T) being activated more potently (rs20541-A/IL-13 Q130 isoform). The IL4 receptor alpha variant rs1801275 (Q576R) is a third member of this axis — it sensitizes the receptor to IL-4/IL-13 signaling, feeding into the same STAT6 pathway. The combined genetic burden across these three variants predicts both disease severity and total IgE levels better than any single variant alone.